April 11, 2016 – Many members of the ovarian cancer community have been concerned about the results of GOG 252 clinical trial, which were released last month at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. OCRFA consulted with a team of our scientific experts, and the consensus of the group is that … Continued
The Lancet has recently published an update to the progression-free survival (PFS) data of theICON6 trial. (The preliminary data was first presented at the European Society of Medical Oncology congress in 2013.) ICON6 is a randomized three-arm, three stage, double-blind, placebo-controlled multi-center Gynaecologic Cancer InterGroup (GCIG) phase III trial. ICON6 is designed to evaluate the safety and … Continued
(March 31, 2016) The Lancet has recently published an update to the progression-free survival (PFS) data of the ICON6 trial. (The preliminary data was first presented at the European Society of Medical Oncology congress in 2013.) ICON6 is a randomized three-arm, three stage, double-blind, placebo-controlled multi-center Gynaecologic Cancer InterGroup (GCIG) phase III trial. ICON6 is designed to … Continued
(March 30, 2016) OCRFA staff and volunteers recently attended the Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer, held March 19-22, 2016 in San Diego. Every year women’s cancer physicians and researchers gather at this meeting to discuss the latest in the care and treatment of women with ovarian and other gynecologic cancers. OCRFA … Continued
By: Annie Ellis, Ovarian Cancer Survivor and Research Advocate Women’s cancer specialists from all over the world convened in San Diego in March to hear about the latest developments in women’s cancer research. This was the fifth SGO annual meeting I’ve attended over the past eight years, and the first that I left with more confusion … Continued
OCRFA staff and volunteers recently attended the Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer, held March 19-22, 2016 in San Diego. Every year women’s cancer physicians and researchers gather at this meeting to discuss the latest in the care and treatment of women with ovarian and other gynecologic cancers. OCRFA Research Advocate and … Continued
Ovarian Cancer Research Alliance today announced the online publication of a collaborative best practices paper entitled, “Understanding Hereditary Cancer in the Era of Multi-Gene Panel Testing.” The paper offers key insights into the changing needs of individuals and family members who might be at risk for hereditary cancer. The paper also includes discussion of how … Continued
(March 22, 2016) A new article in Gynecologic Oncology describes clinical features—some surprising—found in women surviving high-grade serous carcinoma for ten or more years. OCRF Scientific Advisory Committee member and former grantee Douglas A. Levine, MD was senior author of the paper. The study, a joint effort between five academic medical centers, examined 203 long-term … Continued
Q&A with Jill Madden, PhD University of Kansas Medical Center Research Institute, Inc. 2016 Ann Schreiber Mentored Investigator Award OCRFA: Tell me about yourself. Did you always want to be a scientist? Were you interested in science as a child? Jill Madden: I grew up on a farm in rural Alden, Iowa, where livestock … Continued
The Institute of Medicine (IOM) recently released a report commissioned by Congress, Ovarian Cancers: Evolving Paradigms in Research and Care. The report provides an in-depth look at the state of ovarian cancer in the United States. While significant progress has been made in the fight against ovarian cancer in the last few decades, the report … Continued
(March 3, 2016) In a study published in the New England Journal of Medicine this week, researchers report that a dose-dense weekly paclitaxel regimen failed to improve progression-free survival in advanced ovarian cancer versus a conventional regimen and optional bevacizumab (Avastin). Patients treated with weekly paclitaxel plus carboplatin had a median PFS of 14.7 months compared … Continued
Official Trial Name: The Genomic, Epigenomic, and Psychosocial Characteristics of Long-Term Survivors of Ovarian Cancer – Recruitment. Some advanced-stage ovarian cancer patients are long-term survivors of stages III and IV serum ovarian cancer. These patients may provide the key to long-term survival and bring hope to all women with Stages III and IV ovarian cancer. … Continued
Get email updates about research news, action alerts, and ways to join the fight.
